GLP-1 also exerts therapeutic effects on NAFLD through various mechanisms, including ameliorating insulin resistance, inhibiting lipogenesis, and enhancing fatty acid β-oxidation (Ding et al., 2006; Aroor et al., 2015), as well as attenuating gluconeogenesis (Lee et al., 2007) and inflammation (Zhang L. et al., 2013). The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.